Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer

Walter H. Gotlieb*, Mario E. Beiner, Bruria Shalmon, Yaacov Korach, Yaacov Segal, Nissim Zmira, Joure Koupolovic, Gilad Ben-Baruch

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To evaluate the safety of fertility-sparing hormonal therapy for endometrial cancer in young patients. METHODS: We reviewed the clinical and pathologic records of patients diagnosed with endometrial adenocarcinoma before the age of 40, who were treated and followed over a 30-year period in the Division of Gynecologic Oncology. All patients who underwent conservative management with progestins (n = 13) are the subjects of this study. RESULTS: Follow-up was available for all 13 patients, with a mean follow-up of 82 months. All patients responded to treatment within a mean period of 3.5 months, with normal pathology on follow-up endometrial samplings. Six patients had a recurrence within a period extending between 19 and 358 months (median 40 months). Four patients were treated with a second course of progestins, and all had a histologic complete response. As of the time of preparation of this report, nine healthy infants had been born, and all the patients remained without evidence of disease. CONCLUSION: Conservative management of well-differentiated endometrial carcinoma in young patients, combined with assisted reproductive technologies, if needed, does not seem to worsen the prognosis. This approach also provides the possibility of conceiving and carrying a normal pregnancy.

Original languageEnglish
Pages (from-to)718-725
Number of pages8
JournalObstetrics and Gynecology
Issue number4
StatePublished - 1 Oct 2003


Dive into the research topics of 'Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer'. Together they form a unique fingerprint.

Cite this